Newer Antipsychotics Like Zyprexa Double Risk of Death from Heart Failure

The new, expensive drugs such as Risperdal, Zyprexa, and Seroquel were supposed to be more effective than the old treatments for schizophrenia, autism, and dementia. At least that’s how they were marketed to patients and doctors alike. Yet a new study finds these new “wonder drugs” double the risk of death due to heart failure. Furthermore, they haven’t been found to be as effective as the older anti-psychotic drugs.
The most susceptible populations to the risks of rapid weight gain and heart failure are the young and elderly. Professor Wayne Ray of Vanderbilt University authored the study and concluded that the significance of risk compelled prescribing doctors to perform thorough cardiac evaluations prior to giving the drugs to their patients.
Zyprexa, manufactured by Eli Lilly, has been the target of lawsuits ever since it was found that the drug led to rapid weight gain as well as the onset of diabetes in some cases. Besides the civil lawsuits, Eli Lilly has just agreed to pay $1.4 billion to settle criminal and civil investigations into its marketing of the drug Zyprexa. Lilly will pay $615 million to settle the criminal probe and approximately $800 million for the civil investigation. The settlement comes in the midst of the cirminal probe targeting Lilly for promoting Zyprexa for uses for which it had not been approved.